Participating Faculty

Supplements and Featured Publications, Emerging Trends and Formulary Considerations for Atypical Antipsychotics, Volume 11, Issue 8 Suppl

The American Journal of Managed Care

This supplement to contains information on atypical antipsychotics and their cost effectiveness in the treatment of schizophrenia and bipolar disease.

Faculty

David J. Harrison, PhDSenior Manager

Pfizer Inc

Senior Director

New York, NY

Amie T. Joyce, MPH

PharMetrics, Inc

Medical Director

New York, NY

Michael B. Lustik, MS

Science Applications International Corporation

Director

New York, NY

Daniel A. Ollendorf, MPH

Analytic & Consulting Services

Watertown, MA

George M. Simpson, MD

Department of Psychiatry and the Behavioral Sciences

Los Angeles, CA

Richard C. Surles, PhD

Comprehensive NeuroScience, Inc

Senior Statistician

Reston, VA

Disclosure Statement

The American Journal of Managed Care

It is the policy of to have all faculty who participate in programs sponsored by corporate organizations disclose any real or apparent conflicts of interest.

The following participants have declared the following affiliations with corporate organizations:

  • David J. Harrison, PhD Employee: Pfizer Inc

Robin P. Hertz, PhD

Employee:

  • Pfizer Inc
  • Amie T. Joyce, MPH Research Support: Pfizer Inc

Antony D. Loebel, MD

Employee:

  • Pfizer Inc
  • Michael B. Lustik, MS Contractor: Pfizer Inc

Margaret McDonald, PhD

Employee:

  • Pfizer Inc
  • Daniel A. Ollendorf, MPH Research Support: Pfizer Inc

George M. Simpson, MD

Consultant:

  • Pfizer

Research Support:

  • AstraZeneca
  • Janssen Pfizer

Richard C. Surles, PhD

Adviser:

  • Eli Lilly and Company
  • Alan N. Unger, PhD Contractor: Pfizer Inc

The American Journal of Managed Care,

Signed disclosures are on file at the offices of Jamesburg, New Jersey.

This supplement was funded by Pfizer Inc.

Acknowledgments

We would like to thank Laura Brasseur and Debbie Godfrey for their contributions to this supplement.

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.